Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma – a 7.5-year follow-up study
Restricted accessResearch articleFirst published online July, 2011
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma – a 7.5-year follow-up study
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) are key molecules in pericellular proteolysis, a process that plays an important role in tumor invasion and metastasis. In the current study we investigated the prognostic significance of uPA and PAI-1 in primary invasive breast cancer.
Methods and study design
uPA and PAI-1 antigen levels were determined by enzyme-linked immunosorbent assay in cytosols of 177 invasive ductal carcinoma specimens. The prognostic significance of uPA and PAI-1 was assessed for overall survival. The median follow-up time was 90 months.
Results
In univariate analysis, both uPA (third versus first tertile range of values; P = 0.02; HR = 2.08) and PAI-1 (third versus first tertile; P = 0.0007; HR = 3.1) were significant prognostic markers for overall survival. In multivariate analysis only nodal status (N2 vs N0; P = 0.0001; HR = 3.94) and PAI-1 (third versus first tertile; P = 0.004; HR = 3.05) remained significant independent prognostic factors. Both uPA and PAI-1 were correlated with established prognostic markers including histological grade, tumor size and Nottingham index.
Conclusion
Our study with a 7.5-year follow-up confirmed the relation between elevated uPA and PAI-1 values and an aggressive course of invasive breast cancer. The prognostic significance of PAI-1 as an independent marker was proved for the overall group of breast cancer patients and the subgroup of node-positive patients.
Croatian Health Service, Cancer Registry:Cancer mortality in Croatia in 2008 [in Croatian]. Available at http:/www.hzjz.hr/publikacije/umrli_2008.pdf. Accessed 14 February 2008.
JemalA., SiegelR., WardE., HaoY., XuJ., ThunM.J.: Cancer Statistics, 2009.CA Cancer J Clin, 59; 225–249, 2009.
5.
Voorzanger-RousselotN., GarneroP.: Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses.Cancer Treat Rev, 33: 230–283, 2007.
6.
GoldhirschA., WoodW.C., SennH.J., GlickJ.H., GelberR.D.: Meeting highlights: International consensus panel on the treatment of primary breast cancer.J Natl Cancer Inst, 87: 1441–1445, 1995.
7.
GoldhirshA., GlickJ.H., GelberR.D., SennH.J.: Meeting highlights: International consensus panel on the treatment of primary breast cancer.J Natl Cancer Inst, 90: 1601–1608, 1998.
8.
ZujewskiJ., LiuE.T.: The 1998 St. Gallen's consensus conference: an assessment.J Natl Cancer Inst, 90: 1587–1589, 1998.
9.
LowryO.H., RosebroughN.J., FarrA.I., RandallG.: Protein measurement with folin phenol reagent.J Biol Chem, 193: 265–275, 1951.
10.
McGuireW.L.: Estrogen receptors in human breast cancer.J Clin Invest, 52: 73–77, 1973.
11.
GrebenschikovN., Geurts-MoespotA., DeWitteH., HeuvelJ., LeakeR., SweepF., BenraadT.: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI-1) in breast tumor cytosols.Int J Biol Markers, 12: 6–14, 1997.
12.
ClarkT.G., BradburnM.J., LoveS.B., AltmanD.G.: Survival analysis part I: Basic concepts and first analysis.Br J Cancer, 89: 232–238, 2003.
13.
BradburnM.J., ClarkT.G., LoveS.B., AltmanD.G.: Survival analysis part II: Multivariate data analysis – an introduction to concepts and methods.Br J Cancer, 89: 431–436, 2003.
14.
BradburnM.J., ClarkT.G., LoveS.B., AltmanD.G.: Multivariate data analysis – choosing a model and assessing its adequacy and fit.Br J Cancer, 89: 605–611, 2003.
15.
ClarkT.G., BradburnM.J., LoveS.B., AltmanD.G.: Survival analysis part IV: Futher concepts and methods in survival analysis.Br J Cancer, 89: 781–786, 2003.
16.
FoekensJ.A., PetersH.A., LookM.P., PortengenH., SchmittM., KramerM.D., BrünnerN., JänickeF., Meijer-van GelderM.E., Henzen-LogmansS.C., van PuttenW.L.J., KlijnJ.G.M.: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.Cancer Res, 60: 636–643, 2000.
17.
Vrou OffersenB., AlsnerJ., Ege OlsenK., RiisbroR., Brünner, SørensenF.B., SørensenB.S., SchlemmerB.O., OvergaardJ.: A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer.Acta Oncol, 47: 618–632, 2008.
18.
ZemzoumI., KatesR.E., RossJ.S., DettmarP., DuttaM., HenrichsC., YurdsevenS., HöflerH., KiechleM., SchmittM., HarbeckN.: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.J Clin Oncol, 21: 1022–1028, 2003.
19.
HarbeckN., SchmittM., PaepkeS., AllgayerH., KatesR.E.: Tumor-associated proteolytic factors uPA and PAI-1: Critical appraisal of their clinical relevance in breast cancer and their intergration into decision-support algorithms.Crit Rev Clin Lab Sci, 44: 179–201, 2007.
20.
AnneckeK., SchmittM., EulerU., ZermM., PaepkeD., PaepkeS., von Minckwitz, ThomssenC., HarbeckN.: uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.Adv Clin Chem, 45: 31–45, 2008.
21.
JänickeF., PrechtlA., ThomssenC., HarbeckN., MeisnerC., UntchM., SweepCGJF, SelbmannH.K., Graeff, SchmittM.: Randomized adjuvant chemotherapy trial in high-risk, lymph node negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.J Natl Cancer Inst, 93: 913–920, 2001.
22.
HarbeckN., KatesR.E., LookM.P., Meijer-van GelderM.E., KlijnJ.G.M., KrügerA., KiechleM., JänickeF., SchmittM., FoekensJ.A.: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).Cancer Res, 62: 4617–4622, 2002.
23.
LookM.P., van PuttenW.L.J., DuffyM.J., HarbeckN., ChristensenI.J., ThomssenC., KatesR., SpyratosF., FernöM., Eppenberger-CastoriS., SweepCGJF, UlmK., PeyratJ.P., MartinP.M., MagdelenatH., BrünnerN., DugganC., LisboaB.W., BendahlP-O, QuillienV., DaverA., RicolleauG., Meijer-van GelderM.E., MandresP., FietsW.E., BlankensteinM.A., BroëtP., RomainS., DaxenbichlerG., WindbichlerG., CuferT., BorstnarS., KuengW., BeexLVAM, KlijnJ.G.M., O'HigginsN., EppenbergerU., JänickeF., SchmittM., FoekensJ.A.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.J Natl Cancer Inst, 94: 116–128, 2002.
24.
HarrisL., FritscheH., MennelR., NortonL., RavidinP., TaubeS., SomerfieldM.R., HayesD.F., BastR.C.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol, 25: 5287–5312, 2007.
25.
RhaS.Y., YangW.I., GongS.J., KimJ.J., YooN.C., RohJ.K., MinJ.S., LeeK.S., KimB.S., ChungH.C.: Correlation of tissue and blood plasminogen activation system in breast cancer.Cancer Lett, 150: 137–145, 2000.
26.
Grøndahl-HansenJ., ChristensenI.J., RosenquistC., BrünnerN., HenningT., MouridsenH.T., DanøK., Blichert-ToftM.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res, 53: 2513–2521, 1993.
27.
PedersenA.N., ChristensenI.J., StephensR.W., BriandP., MouridsenH.T., DanøK., BrünnerN.: The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.Cancer Res, 60: 6927–6934, 2000.
28.
KnoopA., AndreasenP.A., AndersenJ.A., HansenS., LænkholmA.V., SimonsenA.C.W., AndersenJ., OvergaardJ., RoseC.: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.Br J Cancer, 77: 932–940, 1998.
29.
HansenS., OvergaardJ., RoseC., KnoopA., LænkholmA-V, AndersenJ., SørensenF.B., AndreasenP.A.: Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients.Br J Cancer, 88: 102–108, 1998.
30.
BenraadT.J., Geurts-MoespotJ., Grøndahl-HansenJ., SchmittM., HeuvelJJTM, de WitteJ.H., FoekensJ.A., LeakeR.E., BrünnerN., SweepC.G.J.: Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.Eur J Cancer, 32A: 1371–1381, 1996.
31.
HarbeckN., KatesE., SchmittM.: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.J Clin Oncol, 4: 1000–1007, 2002.
32.
HarbeckN., DettmarP., ThomssenC., BergerK.U., KatesR., HöflerH., JänickeF., GraeffH., SchmittM.: Risk-group discrmination in node-negative breast cancer using invasion and proliferation markers: 6-year median folow-up.Br J Cancer, 80: 419–426, 1999.
33.
MandersP., Tjan-HeijnenV.C.G., SpanP.N., GrebenchtchikovN., Geurts-MoespotA., van TienovenD.T.H., BeexLVAM, SweepFCGJ: Complex of urokinase-type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.Cancer, 101: 486–494, 2004.
